Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
06 mars 2023 16h05 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
24 févr. 2023 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 févr. 2023 17h27 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
08 févr. 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
17 janv. 2023 23h15 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
17 janv. 2023 16h01 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 janv. 2023 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
04 janv. 2023 07h02 HE
|
Fulcrum Therapeutics, Inc.
― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD;...
Fulcrum Therapeutics Announces CEO Transition
04 janv. 2023 07h01 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2022 17h21 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...